Inspire Pharmaceuticals (IRD) insider files to sell 25,000 shares under Rule 144

Rhea-AI Filing Summary

Inspire Pharmaceuticals, Inc. reported that insider Benjamin Yerxa filed to sell common stock under Rule 144. The planned sale involves 25,000 shares of common stock, related to an RSU grant vest dated 07/22/2026, with sales noted as occurring on 07/23/2026 through Raymond James & Associates on NASDAQ. The filing also lists a prior sale of 7,470 common shares on 04/23/2026 for an aggregate value of $39,121.00.

Key Figures

Planned shares to be sold: 25,000 shares Previous shares sold: 7,470 shares Aggregate value of prior sale: $39,121.00 +3 more

6 metrics

Planned shares to be sold 25,000 shares Common stock tied to RSU grant vest dated 07/22/2026

Previous shares sold 7,470 shares Common stock sale on 04/23/2026

Aggregate value of prior sale $39,121.00 Value of 7,470 common shares sold on 04/23/2026

Broker-related share figure 7,429 shares Share-related figure listed with Raymond James & Associates

Broker-related value figure $22,064.13 Value-related figure listed with Raymond James & Associates

Planned sale date 07/23/2026 Date associated with planned common stock sale

Key Terms

Rule 144, RSU GRANT VEST, Common

3 terms

Rule 144 regulatory

"144: Securities To Be Sold"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU GRANT VEST financial

"Common | 07/22/2026 | RSU GRANT VEST | Issuer"

Common financial

"Common | Raymond James & Associates 880 Carillon Parkway"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 12:47 PM Accepted by SEC EDGAR 07/23/2026 - 12:46 PM Learn about SEC filing dates

FAQ

What stock sale is disclosed for Inspire Pharmaceuticals (IRD) in this Form 144?

The Form 144 discloses a planned sale of 25,000 shares of Inspire Pharmaceuticals common stock. These shares are tied to an RSU grant vest dated 07/22/2026, with sales noted as occurring on 07/23/2026 through a broker on NASDAQ.

Who is the reporting person in the Inspire Pharmaceuticals (IRD) Form 144?

The reporting person is Benjamin Yerxa, associated with Inspire Pharmaceuticals, Inc. His address is listed as 4222 Emperor Blvd., 470, Durham, NC 27703, indicating his connection to the company in the context of this Rule 144 stock sale.

How many Inspire Pharmaceuticals (IRD) shares were sold previously in the last 3 months?

The filing notes a prior sale of 7,470 common shares of Inspire Pharmaceuticals on 04/23/2026. The aggregate value for this earlier transaction is reported as $39,121.00, giving context to the insider’s recent trading activity.

What is the nature of the Inspire Pharmaceuticals (IRD) shares being sold?

The planned sale of 25,000 shares is linked to an RSU grant vest dated 07/22/2026. This means the shares originate from restricted stock units that vested, and the filing indicates they may be sold for cash starting 07/23/2026.

Which broker and market are involved in the Inspire Pharmaceuticals (IRD) Form 144 sale?

The common stock planned for sale is associated with Raymond James & Associates as broker, with trading indicated on NASDAQ. The Form 144 provides these details as part of the securities information for the planned disposition.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	7429	22064.13	82570000	07/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/22/2026	RSU GRANT VEST	Issuer			25000	07/23/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BENJAMIN YERXA c/o INSPIRE PHARMACEUTICALS, INC. 4222 EMPEROR BLVD., 470 Durham NC 27703	Common	04/23/2026	7470	39121.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)